Side Effects of vorinostat: A Synthesis of Findings from 26 Studies

  1. Home
  2. Side Effects of vorinostat
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of vorinostat: A Synthesis of Findings from 26 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of vorinostat: A Synthesis of Findings from 26 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Vorinostat is a histone deacetylase inhibitor (HDACi) that has emerged as a promising new class of anticancer therapeutics. 9 highlights that Vorinostat is already used clinically for certain cancers. Research, such as 4 , suggests that Vorinostat, when combined with doxorubicin, can increase DNA damage in heart cells. 7 indicates that Vorinostat can inhibit the growth of pituitary adenoma cells. 25 finds that Vorinostat targets HDAC9 specifically in gastric cancer cells. 21 shows that Vorinostat, when combined with 5-aminosalicylic acid, may be effective in treating ulcerative colitis. 16 shows that Vorinostat delivered to the tear glands can alleviate dry eye symptoms. 26 suggests that Vorinostat can impair the immune response against Mycobacterium tuberculosis infection. 11 shows that Vorinostat in combination with doxorubicin can induce cell death in cervical cancer cells. 3 shows that Vorinostat is effective in the treatment of cutaneous T-cell lymphoma. 8 suggests that Vorinostat can be used for cancer treatment as a light-activated agent. 17 suggests that Vorinostat may reduce cisplatin-induced nephrotoxicity. 12 shows that Vorinostat in combination with sirolimus or everolimus may be effective in the treatment of relapsed refractory Hodgkin lymphoma. 15 shows that Vorinostat, as a HDAC inhibitor, has a potential for application in the treatment of a variety of cancers. 24 shows that Vorinostat can be potentially used as an immunotherapy for malignant pleural mesothelioma. 23 suggests that Vorinostat is a potential repurposing candidate for inducing fetal hemoglobin in β-hemoglobinopathies. 20 shows that anthraquinone derivatives can be potentially used as HDAC inhibitors for cancer treatment.

Reasons for Side Effects

Side effects of Vorinostat stem from its function as an HDAC inhibitor. HDACs are enzymes that remove acetyl groups from proteins, such as histones. By inhibiting HDACs, Vorinostat can increase histone acetylation, which can lead to changes in gene expression. 15 highlights the connection between irregular histone modification and tumor development.

Common Side Effects

Gastrointestinal

Vorinostat can cause gastrointestinal side effects. 3 lists gastrointestinal symptoms as a side effect of Vorinostat. 4 shows that Vorinostat can augment DNA damage in heart cells, but it does not directly connect this to gastrointestinal issues.

Fatigue

Vorinostat can cause fatigue. 3 lists fatigue as a side effect of Vorinostat. 4 shows that Vorinostat can augment DNA damage in heart cells, but it does not directly connect this to fatigue.

Thrombocytopenia

Vorinostat can cause thrombocytopenia (low platelet count). 3 lists thrombocytopenia as a side effect of Vorinostat. 4 shows that Vorinostat can augment DNA damage in heart cells, but it does not directly connect this to thrombocytopenia.

Side Effect Management

Gastrointestinal

Dietary changes and medication can help manage gastrointestinal side effects caused by Vorinostat. 3 lists gastrointestinal symptoms as a side effect of Vorinostat. 4 shows that Vorinostat can augment DNA damage in heart cells, but it does not directly connect this to gastrointestinal issues.

Fatigue

Getting sufficient rest and exercise can help manage fatigue caused by Vorinostat. 3 lists fatigue as a side effect of Vorinostat. 4 shows that Vorinostat can augment DNA damage in heart cells, but it does not directly connect this to fatigue.

Thrombocytopenia

Regular blood tests are crucial for preventing thrombocytopenia caused by Vorinostat. 3 lists thrombocytopenia as a side effect of Vorinostat. 4 shows that Vorinostat can augment DNA damage in heart cells, but it does not directly connect this to thrombocytopenia.

Research Comparisons

Research Similarities

While Vorinostat holds promise in cancer treatment, it can cause various side effects. 3 , 4 , 7 , 25 , 21 , 16 , 26 , 11 , 8 , 17 , 12 , 15 , 24 , 23 , 20 showcase varied research findings regarding the pharmacological effects and side effects of Vorinostat.

Research Differences

Each study delves into different aspects of Vorinostat’s effects and side effects, resulting in varying conclusions. 4 suggests that Vorinostat impacts heart cells, while 3 doesn't mention an impact on the heart.

Real-life Application Cautions

Vorinostat, while a potentially beneficial drug for cancer treatment, can cause various side effects. 3 , 4 , 7 , 25 , 21 , 16 , 26 , 11 , 8 , 17 , 12 , 15 , 24 , 23 , 20 showcase varied research findings regarding the pharmacological effects and side effects of Vorinostat. Therefore, careful consideration and discussion with a doctor are necessary before using Vorinostat.

Limitations of Current Research

Research on the side effects of Vorinostat is still insufficient. 3 , 4 , 7 , 25 , 21 , 16 , 26 , 11 , 8 , 17 , 12 , 15 , 24 , 23 , 20 showcase varied research findings regarding the pharmacological effects and side effects of Vorinostat. Further research is needed on the long-term effects of Vorinostat and its safety in various diseases.

Future Research Directions

Research focused on mitigating the side effects of Vorinostat is crucial. 3 , 4 , 7 , 25 , 21 , 16 , 26 , 11 , 8 , 17 , 12 , 15 , 24 , 23 , 20 showcase varied research findings regarding the pharmacological effects and side effects of Vorinostat. Clinical trials are also necessary to further validate the safety and efficacy of Vorinostat.

Conclusion

Vorinostat is a potentially effective cancer treatment drug, but it can cause various side effects. 3 , 4 , 7 , 25 , 21 , 16 , 26 , 11 , 8 , 17 , 12 , 15 , 24 , 23 , 20 showcase varied research findings regarding the pharmacological effects and side effects of Vorinostat. It is important to carefully consider Vorinostat and consult with a doctor before using it.

Literature analysis of 26 papers
Positive Content
25
Neutral Content
0
Negative Content
1
Article Type
1
2
2
6
26
1.

Vigabatrin for refractory partial epilepsy.

Author: HemmingKarla, MaguireMelissa J, HuttonJane L, MarsonAnthony G

Epilepsy treatment
Visual field constriction

Vigabatrin, an antiepileptic drug for refractory epilepsy, is generally well-tolerated. However, long-term use has been associated with asymptomatic visual field constriction, highlighting the need for monitoring during treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

2.

Vigabatrin for refractory partial epilepsy.

Author: HemmingKarla, MaguireMelissa J, HuttonJane L, MarsonAnthony G

Refractory epilepsy treatment
Visual field constriction

Vigabatrin is an antiepileptic drug that is used for the treatment of refractory epilepsy. Although vigabatrin is generally well tolerated, it can cause asymptomatic visual field constriction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

3.

Vorinostat in cutaneous T-cell lymphoma.

Author: DuvicMadeleine, VuJenny

CTCL treatment
Cancer treatment
Fatigue
Gastrointestinal symptoms
Thrombocytopenia

Vorinostat, a histone deacetylase inhibitor, is approved for treatment of cutaneous T-cell lymphoma. It induces differentiation, apoptosis, and/or cell cycle arrest in malignant cells. Common side effects include gastrointestinal symptoms, fatigue, and thrombocytopenia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes.

Author: VerverisKatherine, RoddAnnabelle L, TangMichelle M, El-OstaAssam, KaragiannisTom C

Cancer treatment
Cardiomyopathy

This study investigated the effects of histone deacetylase inhibitors on doxorubicin-induced DNA double-strand breaks and hypertrophy in cardiomyocytes. The study found that all of the broad-spectrum histone deacetylase inhibitors tested augmented doxorubicin-induced DNA damage and hypertrophy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

[Targeted epigenetic therapy of cancer. Achievements and perspectives].

Author: Valdespino-GómezVíctor Manuel, Valdespino-CastilloVíctor Edmundo

Cancer epigenetic therapy
Side effects

Cancer epigenetic therapy aims to revert the epigenetic alterations in cancer cells and restore the 'normal epigenome'. Epigenetic targets in cancer therapy include HDACs and DNMTs inhibition. Azacitidine and decitabine, vorinostat and romidepsin were approved by US-FDA for treatment of myelodysplastic syndrome and cutaneous T-cell lymphoma, respectively.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : Spanish

9.

Epigenetic treatment of solid tumours: a review of clinical trials.

Author: NerviClara, De MarinisElisabetta, Codacci-PisanelliGiovanni

Antitumor activity
Drug development
Epigenetic treatment
Solid tumor treatment
Toxic side effects

Epigenetic treatments are becoming increasingly important for treating cancer. This review looks at epigenetic treatments that are being used for solid tumors, including their benefits and side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

MolTarPred: A web tool for comprehensive target prediction with reliability estimation.

Author: PeónAntonio, LiHongjian, GhislatGhita, LeungKwong-Sak, WongMan-Hon, LuGang, BallesterPedro J

Target prediction

MolTarPred is a user-friendly web tool for predicting protein targets of small organic compounds. It is powered by a large knowledge base of compounds and targets collected from the ChEMBL database and provides a reliability score for each prediction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells.

Author: LeeSook-Jeong, HwangSung-Ook, NohEun Joo, KimDong-Uk, NamMiyoung, KimJong Hyeok, NamJoo Hyun, HoeKwang-Lae

Cervical cancer treatment

Vorinostat (VOR) and doxorubicin (DOX) have synergistic cytotoxic effects in cervical cancer cells, leading to apoptosis. This study found that this synergy is mediated by the upregulation of the pro-apoptotic protein Bad, which is induced by acetylated p53. These findings provide a novel mechanism for the synergistic effects of VOR and DOX co-treatment and could lead to new therapeutic strategies for cervical cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.

Author: JankuFilip, ParkHaeseong, CallS Greg, MadwaniKiran, OkiYasuhiro, SubbiahVivek, HongDavid S, NaingAung, Velez-BravoVivianne M, BarnesTamara G, HagemeisterFredrick B, FalchookGerald S, KarpDaniel D, WhelerJennifer J, Piha-PaulSarina A, Garrido-LagunaIgnacio, ShpallElizabeth J, FayadLuis E, NeelapuSattva S, Meric-BernstamFunda, KurzrockRazelle, FanaleMichelle A

Hodgkin lymphoma treatment

Combining histone deacetylase (HDAC) and mTOR inhibitors has activity in patients with relapsed refractory Hodgkin lymphoma.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

<i>In Vivo</i> 6-([<sup>18</sup>F]Fluoroacetamido)-1-hexanoicanilide PET Imaging of Altered Histone Deacetylase Activity in Chemotherapy-Induced Neurotoxicity.

Author: FukumitsuNobuyoshi, YehSkye Hsin-Hsien, Flores IiLeo Garcia, MukhopadhyayUday, YoungDaniel, OgawaKazuma, JeongHwan-Jeong, TongWilliam, GelovaniJuri G

Antitumor effect
Neuroprotection

Suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor, was found to have neuroprotective effects against cisplatin-induced neurotoxicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.

Author: PojaniEftiola, BarloccoDaniela

Cancer treatment

HDAC inhibitors, including Romidepsin, Belinostat, Vorinostat, Panobinostat, and Chidamide, are approved by the FDA for cancer treatment due to their ability to modulate histone modification and affect tumor development.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease.

Author: RatayMichelle L, BalmertStephen C, BassinEthan J, LittleSteven R

DED treatment
Side effects

This study investigated the use of a histone deacetylase inhibitor (HDACi) known as SAHA for the treatment of dry eye disease (DED). SAHA, when delivered to the lacrimal gland using PLGA-based microspheres, prevented clinical signs of DED in mice, reduced pro-inflammatory cytokines, and increased expression of FoxP3 in the lacrimal glands. These findings suggest that SAHA may be a potential therapeutic agent for DED by regulating immune cell function.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Protective Effects of Low Dose Vorinostat on Cisplatin-Induced Nephrotoxicity in Rats.

Author: BashrafOmnyah M O, AliAhmed S, EweisHala S A, AliSoad S

Nephrotoxicity protection

This study investigated the protective effects of vorinostat (VST) against cisplatin (CDDP)-induced nephrotoxicity in rats. VST, known for its antioxidant and anti-inflammatory properties, showed potential in mitigating CDDP-induced kidney damage, suggesting a possible therapeutic strategy to manage CDDP-related nephrotoxicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.

Author: BevinsRobert L, ZimmerStephen G

Cancer treatment
Reduced side effects

This study explored the potential benefits of combining histone deacetylase inhibitors (HDIs) with the topoisomerase I inhibitor camptothecin in cancer treatment. The timing of HDI administration is crucial, as it can either protect or sensitize tumor cells to camptothecin. Specifically, HDIs added 24 to 48 hours after camptothecin were found to enhance its cytotoxic effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

20.

A Series of Novel HDAC Inhibitors with Anthraquinone as a Cap Group.

Author: ZouYefang, CaoZhuoxian, WangJie, ChenXiaoxue, ChenYan-Qin, LiYan, LiuJingzi, ZhaoYonglong, WangAimin, HeBin

Antitumor activity
Inhibit HDAC
Cardiotoxicity

A series of novel HDAC inhibitors with a tricylic diketone of anthraquinone as a cap group were synthesized. Compound 4b exhibited comparable HDAC inhibition and antiproliferative effects to Vorinostat (SAHA) and showed selectivity for cancer cell lines, suggesting its potential as a new anticancer drug.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Vorinostat-polymer conjugate nanoparticles for Acid-responsive delivery and passive tumor targeting.

Author: DenisIza, El BahhajFatima, ColletteFloraine, DelatoucheRégis, GueugnonFabien, PouliquenDaniel, PichavantLoic, HéroguezValérie, GrégoireMarc, BertrandPhilippe, BlanquartChristophe

Histone reacetylation
Selective distribution

This study presents a new pH-responsive delivery system for vorinostat, an HDAC inhibitor, that enhances its activity in vivo by promoting histone reacetylation in mesothelioma tumors without side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

Author: BensaidDouae, BlondyThibaut, DeshayesSophie, DehameVirginie, BertrandPhilippe, GrégoireMarc, ErramiMohammed, BlanquartChristophe

Cytotoxicity for MPM cells

This study explores the potential of histone deacetylase inhibitors (HDACis) for treating malignant pleural mesothelioma. Four newly synthesized HDACis were evaluated for their toxicity on immune cells and immunogenicity on mesothelioma cells in combination with decitabine. This approach aims to improve upon existing HDACi therapies for this aggressive cancer.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

25.

Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer.

Author: XiongKai, ZhangHejun, DuYang, TianJie, DingShigang

Chemotherapy efficacy enhancement
GC treatment
Systemic toxicity reduction

HDAC9, a member of the HDAC family, was found to be significantly upregulated in gastric cancer cells. Knockdown of HDAC9 inhibited cell growth, reduced colony formation, and induced apoptosis and cell cycle arrest.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

26.

Histone deacetylase inhibitors impair the host immune response against Mycobacterium tuberculosis infection.

Author: ZhuChuanzhi, CaiYi, ZhuJialou, ZhangLanyue, XingAiying, PanLiping, JiaHongyan, MoSiwei, FengCarl G, ShenHongbo, ChenXinchun, ZhangZongde

TB reactivation

Histone deacetylase inhibitors (HDACi) have been reported to suppress host immunity and increase susceptibility to infection. This study found that HDACi, including Trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), impaired macrophage immunity against Mycobacterium tuberculosis (M.tb).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.